Your session is about to expire
← Back to Search
Virus Therapy
VM-202 for Diabetic Neuropathy
Phase 2
Waitlist Available
Led By Christine N. Sang, MD, MPH
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 90, day 180, day 270, day 365
Awards & highlights
Study Summary
This trial is testing a new drug to see if it is safe and effective in treating people with a specific type of nerve pain.
Eligible Conditions
- Diabetic Neuropathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 90, day 180, day 270, day 365
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 90, day 180, day 270, day 365
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Morphine
Secondary outcome measures
Efficacy- Change in Average Pain Intensity
Opioid use - mean dose
Opioid use - percent change from baseline
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: VM-202Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,609 Previous Clinical Trials
11,470,277 Total Patients Enrolled
Christine N. Sang, MD, MPHPrincipal InvestigatorBrigham and Women's Hospital
2 Previous Clinical Trials
52 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Missouri
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Share this study with friends
Copy Link
Messenger